Re-Engineering Basic and Clinical Research to Catalyze Translational Nanoscience

描述(由申请人提供)： 临床研究和基础研究之间的障碍，以及涉及的日益复杂的 进行转化性研究，使得将新的科学知识转化到临床--以及临床需求--变得更加困难。这次会议的目标是激励 翻译纳米科学这一新兴实践的发展。演讲者包括纳米科学领域的领导者和霍华德·休斯医学研究所的临床转化研究领导者 (HHMI)S患者导向研究人员计划和美国国立卫生研究院综合临床研究中心(GCRC)以及临床和翻译科学奖(CTSA)联盟计划。与其他会议相比，这次会议通过以下方式提供附加值：(1)由材料、生物和物理科学学科的杰出科学家和工程师组成的多学科小组的演讲，以开发纳米设备和纳米技术，以及具有基因组学、蛋白质组学、多器官系统、分子和途径方面的专业知识的有远见的临床研究人员；(2)介绍作为生物仿生、纳米机械、纳米纤维和聚合物纳米结构作为生物材料和纳米级制造设备、传感器和实验室诊断的纳米结构研究的前沿方法；(3)激发独特的变革性、新颖性和整合性策略，以催化纳米结构和纳米颗粒技术在临床实践中的应用，这些技术能够针对不同的细胞和细胞外元素，将药物、遗传物质和诊断试剂运送到特定位置。这包括加快纳米尺度技术的开发，使其能够在体内探测细胞和亚细胞生理学；(4)确定纳米医学中未来翻译纳米科学的优先事项，以促进药物输送、药物和治疗开发、体内成像、体外诊断、活性植入物和组织修复/再生；以及(5)实施青年研究人员计划，通过该计划，将邀请初级研究人员，特别是妇女和未被充分代表的少数群体，提出令人兴奋的新发现和研究方法，这些发现和研究方法很有可能加速基础纳米科学和翻译纳米科学的发现。最终，这次会议将提供关于纳米科学发现如何迅速转化为临床实践的关键新见解，以彻底改变医疗保健。

DESCRIPTION (provided by the applicant): Barriers between clinical and basic research, along with the ever the increasing complexities involved in conducting translational research, are making it more difficult to translate new scientific knowledge to the clinic - and clinical needs back to the bench. The objective of this conference is to energize the development of the nascent practice of translational nanoscience. Speakers include leaders in the field of nanoscience and leaders in clinical translational research from the Howard Hughes Medical Institute (HHMI)'s Patient-Oriented Research Investigator's Program and NIH's General Clinical Research Center (GCRC) and Clinical and Translational Science Awards (CTSA) Consortium programs. The conference provides added value compared to others by: (1) including talks from a multidisciplinary group of outstanding scientists and engineers working in the materials, biological and physical science disciplines to develop nanodevices and nanotechnologies, together with visionary clinical researchers with expertise in genomics, proteomics, multiple organ systems, molecules and pathways implicated in common human diseases; (2) presenting cutting-edge approaches to studying nanostructures that act as biological mimetics, nanomachines, nanofibers and polymeric nanoconstructs as biomaterials and nanoscale fabrication devices, sensors and laboratory diagnostics; (3) stimulating uniquely transformative, novel, and integrative strategies to catalyze the application to clinical practice of nanostructures and nanoscale particulate technologies capable of targeting different cells and extracellular elements to deliver drugs, genetic materials and diagnostic agents to specific locations. This includes acceleration of the development of nanoscale techniques that enable in vivo probes of cellular and subcellular physiology; (4) establishing priorities for future translational nanoscience in nanomedicine to facilitate drug delivery, drug and therapeutic development, in vivo imaging, in vitro diagnostics, active implants and tissue repair/regeneration; and (5) implementing a Young Investigator Program, by which junior investigators, specifically women and underrepresented minorities, will be solicited to present exciting new findings and research approaches that have a high likelihood of accelerating basic nanoscience and translational nanoscience discoveries. Ultimately, this conference will provide critical new insights into how nanoscience discoveries can be rapidly translated into clinical practice to revolutionize healthcare.